Comparative Pharmacology
Head-to-head clinical analysis: MOLINDONE HYDROCHLORIDE versus ORAP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOLINDONE HYDROCHLORIDE versus ORAP.
MOLINDONE HYDROCHLORIDE vs ORAP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D2 receptor antagonist; also blocks serotonin 5-HT2A receptors and alpha-adrenergic receptors.
Orap (pimozide) is a diphenylbutylpiperidine antipsychotic that selectively blocks dopamine D2 receptors in the central nervous system, with weak antagonism at alpha1-adrenergic and H1-histamine receptors. Its anti-dyskinetic effect in Tourette syndrome may also involve blockade of calcium channels.
50-225 mg/day orally in 3-4 divided doses; usual effective dose 50-75 mg/day; maximum 225 mg/day.
Initial: 2 mg orally twice daily; maintenance: 2-10 mg twice daily. Maximum 20 mg/day.
None Documented
None Documented
1.5-2 hours; shorter than typical antipsychotics, requiring multiple daily dosing.
Clinical Note
moderateVorapaxar + Tranilast
"Vorapaxar may increase the anticoagulant activities of Tranilast."
Clinical Note
moderateVorapaxar + Resveratrol
"Vorapaxar may increase the anticoagulant activities of Resveratrol."
Clinical Note
moderateVorapaxar + Nimesulide
"Vorapaxar may increase the anticoagulant activities of Nimesulide."
Clinical Note
moderateVorapaxar + Epoprostenol
"Vorapaxar may increase the antiplatelet activities of Epoprostenol."
Terminal elimination half-life is 20–40 hours (mean 27 hours). Steady-state achieved in 4–7 days.
Renal: 65-70% as metabolites and unchanged drug; Fecal: 20-25%; Biliary: minor.
Primarily hepatic metabolism; approximately 40% excreted in urine as metabolites, 15% in feces as unchanged drug and metabolites.
Category C
Category C
Antipsychotic
Antipsychotic